البلد: جنوب أفريقيا
اللغة: الإنجليزية
المصدر: South African Health Products Regulatory Authority (SAHPRA)
Schering
SCHERIPROCT SUPPOSITORIES SCHEDULING STATUS S4 PROPRIETARY NAME (and dosage form): SCHERIPROCT SUPPOSITORIES COMPOSITION 1 suppository contains prednisolone caproate (1,4-pregnadiene-3,20-dione-11beta-17alpha,21-triol-21-caproate) 1,3 mg and cinchocaine hydrochloride as the hydrochloride of (2-butoxy-N-(2-diethylaminoethyl)cinchonamide) 1 mg. PHARMACOLOGICAL CLASSIFICATION A. 11.8 Suppositories. PHARMACOLOGICAL ACTION Prednisolone exerts an antiinflammatory and antipruritic effect. Capillary dilatation, intercellular oedema and tissue infiltration regress; capillary proliferation is suppressed. As a local anaesthetic, cinchocaine eases the pain. INDICATIONS Short term symptomatic relief of perianal discomfort, inflammation and itching caused by thrombosed haemorrhoids, anal fissure and pruritus ani. CONTRA-INDICATIONS Hypersensitivity to any of the ingredients. Viral infections, primary bacterial or fungal infections in the treatment area. Secondary infections of the skin in the absence of appropriate antiinfective therapy. Known sensitivity to local anaesthetics. Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed percutaneously, teratogenicity following topical application cannot be excluded. Therefore, Scheriproct should not be used during pregnancy. The excretion of effective amounts of glucocorticoid with the breast milk is improbable. WARNINGS This product should not be used continuously for more than 7 days. If symptoms do not disappear quickly, discontinue treatment and consult your doctor. Certain anal disorders require specific treatment and a proctological examination. In case of bleeding, consult a doctor promptly. DOSAGE AND DIRECTIONS FOR USE The anal region should be cleaned thoroughly before using Scheriproct, which is best applied اقرأ الوثيقة كاملة